Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1396


Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?

Rozovski U, Keating MJ, Estrov Z.

Acta Haematol. 2018;140(1):51-54. doi: 10.1159/000491382. Epub 2018 Aug 16. Review.


Pathology in Practice.

Edwards EE, Birch SM, Hoppes SM, Keating MK, Stoica G.

J Am Vet Med Assoc. 2018 Aug 15;253(4):423-426. doi: 10.2460/javma.253.4.423. No abstract available.


Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR.

Haematologica. 2018 Jul 5. pii: haematol.2018.190132. doi: 10.3324/haematol.2018.190132. [Epub ahead of print]


Multifocal Soft Tissue Cryptococcosis in a Renal Transplant Recipient: The Importance of Suspecting Atypical Pathogens in the Immunocompromised Host.

Ajmal S, Keating M, Wilhelm M.

Exp Clin Transplant. 2018 Jun 28. doi: 10.6002/ect.2017.0292. [Epub ahead of print]


The CCC Complex COMManDs Control of LDL Cholesterol Levels.

Keating MF, Calkin AC.

Circ Res. 2018 Jun 8;122(12):1629-1631. doi: 10.1161/CIRCRESAHA.118.313074. No abstract available.


A Case of Prototheca zopfii Genotype 1 Infection in a Dog (Canis lupus familiaris).

Silveira CS, Cesar D, Keating MK, DeLeon-Carnes M, Armién AG, Luhers M, Riet-Correa F, Giannitti F.

Mycopathologia. 2018 Jun 6. doi: 10.1007/s11046-018-0274-5. [Epub ahead of print]


Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.

Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V.

Oncotarget. 2018 May 18;9(38):24980-24991. doi: 10.18632/oncotarget.25166. eCollection 2018 May 18.


Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0132-y. [Epub ahead of print]


STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Oncotarget. 2018 Apr 20;9(30):21268-21280. doi: 10.18632/oncotarget.25066. eCollection 2018 Apr 20.


Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib.

Bergman JC, Ly TY, Keating MM, Hull PR.

J Cutan Med Surg. 2018 May 1:1203475418775663. doi: 10.1177/1203475418775663. [Epub ahead of print]


Prototheca zopfii Colitis in Inherited CARD9 Deficiency.

Sari S, Dalgic B, Muehlenbachs A, DeLeon-Carnes M, Goldsmith CS, Ekinci O, Jain D, Keating MK, Vilarinho S.

J Infect Dis. 2018 Jul 2;218(3):485-489. doi: 10.1093/infdis/jiy198.


Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Jun 15;124(12):2534-2540. doi: 10.1002/cncr.31370. Epub 2018 Apr 12.


Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

Oncoimmunology. 2018 Jan 15;7(4):e1417720. doi: 10.1080/2162402X.2017.1417720. eCollection 2018.


iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.


Candida pneumonia with severe clinical course, recovery with antifungal therapy and unusual pathologic findings: A case report.

Dermawan JKT, Ghosh S, Keating MK, Gopalakrishna KV, Mukhopadhyay S.

Medicine (Baltimore). 2018 Jan;97(2):e9650. doi: 10.1097/MD.0000000000009650.


Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.

Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z.

Leukemia. 2018 Feb 20. doi: 10.1038/s41375-018-0059-3. [Epub ahead of print] No abstract available.


Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167. [Epub ahead of print]


Sprouting angiogenesis induces significant mechanical heterogeneities and ECM stiffening across length scales in fibrin hydrogels.

Juliar BA, Keating MT, Kong YP, Botvinick EL, Putnam AJ.

Biomaterials. 2018 Apr;162:99-108. doi: 10.1016/j.biomaterials.2018.02.012. Epub 2018 Feb 6.


The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K.

Front Immunol. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773. eCollection 2017.


Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A.

Blood. 2018 Apr 19;131(16):1820-1832. doi: 10.1182/blood-2017-11-817296. Epub 2018 Jan 22.


Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy.

Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P.

PLoS Biol. 2017 Dec 11;15(12):e1002616. doi: 10.1371/journal.pbio.1002616. eCollection 2017 Dec.


The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.

Br J Haematol. 2018 Jan;180(1):33-40. doi: 10.1111/bjh.15018. Epub 2017 Nov 21.


Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V.

Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3.


Interpreting Mobile and Handheld Air Sensor Readings in Relation to Air Quality Standards and Health Effect Reference Values: Tackling the Challenges.

Woodall GM, Hoover MD, Williams R, Benedict K, Harper M, Soo JC, Jarabek AM, Stewart MJ, Brown JS, Hulla JE, Caudill M, Clements AL, Kaufman A, Parker AJ, Keating M, Balshaw D, Garrahan K, Burton L, Batka S, Limaye VS, Hakkinen PJ, Thompson B.

Atmosphere (Basel). 2017;8(10):182. doi: 10.3390/atmos8100182. Epub 2017 Sep 21.


A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.

Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.


Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K.

Leukemia. 2018 Apr;32(4):960-970. doi: 10.1038/leu.2017.304. Epub 2017 Oct 3.


Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.

Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V.

Leuk Lymphoma. 2018 Jun;59(6):1427-1438. doi: 10.1080/10428194.2017.1376747. Epub 2017 Oct 3.


The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.

Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V.

Neoplasia. 2017 Oct;19(10):762-771. doi: 10.1016/j.neo.2017.07.004. Epub 2017 Aug 30.


B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.

Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V.

Mol Cancer Res. 2017 Dec;15(12):1692-1703. doi: 10.1158/1541-7786.MCR-17-0026. Epub 2017 Aug 23.


Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.

Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A.

Haematologica. 2017 Dec;102(12):e494-e496. doi: 10.3324/haematol.2017.171561. Epub 2017 Aug 10. No abstract available.


Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Hacken ET, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA.

Haematologica. 2017 Oct;102(10):e394-e396. doi: 10.3324/haematol.2017.169102. Epub 2017 Jul 27. No abstract available.


Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy.

Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V.

Br J Haematol. 2017 Oct;179(2):266-271. doi: 10.1111/bjh.14859. Epub 2017 Jul 24.


Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K.

Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20.


Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Int J Cancer. 2017 Nov 15;141(10):2076-2081. doi: 10.1002/ijc.30892. Epub 2017 Aug 4.


Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.

Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5.


Evaluation of Placental and Fetal Tissue Specimens for Zika Virus Infection - 50 States and District of Columbia, January-December, 2016.

Reagan-Steiner S, Simeone R, Simon E, Bhatnagar J, Oduyebo T, Free R, Denison AM, Rabeneck DB, Ellington S, Petersen E, Gary J, Hale G, Keating MK, Martines RB, Muehlenbachs A, Ritter J, Lee E, Davidson A, Conners E, Scotland S, Sandhu K, Bingham A, Kassens E, Smith L, St George K, Ahmad N, Tanner M, Beavers S, Miers B, VanMaldeghem K, Khan S, Rabe I, Gould C, Meaney-Delman D, Honein MA, Shieh WJ, Jamieson DJ, Fischer M, Zaki SR; U.S. Zika Pregnancy Registry Collaboration; Zika Virus Response Epidemiology and Surveillance Task Force Pathology Team.

MMWR Morb Mortal Wkly Rep. 2017 Jun 23;66(24):636-643. doi: 10.15585/mmwr.mm6624a3.


Factors influencing professional life satisfaction among neurologists.

Teixeira-Poit SM, Halpern MT, Kane HL, Keating M, Olmsted M.

BMC Health Serv Res. 2017 Jun 19;17(1):409. doi: 10.1186/s12913-017-2343-8.


Spatial distributions of pericellular stiffness in natural extracellular matrices are dependent on cell-mediated proteolysis and contractility.

Keating M, Kurup A, Alvarez-Elizondo M, Levine AJ, Botvinick E.

Acta Biomater. 2017 Jul 15;57:304-312. doi: 10.1016/j.actbio.2017.05.008. Epub 2017 May 5.


Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections.

Fuentes-Mattei E, Giza DE, Shimizu M, Ivan C, Manning JT, Tudor S, Ciccone M, Kargin OA, Zhang X, Mur P, do Amaral NS, Chen M, Tarrand JJ, Lupu F, Ferrajoli A, Keating MJ, Vasilescu C, Yeung SJ, Calin GA.

EBioMedicine. 2017 Jun;20:182-192. doi: 10.1016/j.ebiom.2017.04.018. Epub 2017 Apr 19.


Establishing Linkages Between Distributed Survey Responses and Consumer Wearable Device Datasets: A Pilot Protocol.

Brinton JE, Keating MD, Ortiz AM, Evenson KR, Furberg RD.

JMIR Res Protoc. 2017 Apr 27;6(4):e66. doi: 10.2196/resprot.6513.


Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.

Abou Zahr A, Bose P, Keating MJ.

Expert Opin Pharmacother. 2017 Jun;18(9):857-873. doi: 10.1080/14656566.2017.1324420. Epub 2017 May 16. Review.


Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM.

Ann Oncol. 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163.


Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.

Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM.

Br J Haematol. 2017 May;177(4):567-577. doi: 10.1111/bjh.14596. Epub 2017 Mar 14.


Vascularization and innervation of slits within polydimethylsiloxane sheets in the subcutaneous space of athymic nude mice.

Gurlin RE, Keating MT, Li S, Lakey JR, de Feraudy S, Shergill BS, Botvinick EL.

J Tissue Eng. 2017 Jan 30;8:2041731417691645. doi: 10.1177/2041731417691645. eCollection 2017 Jan-Dec.


Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.

Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V.

Oncotarget. 2017 Mar 7;8(10):16259-16274. doi: 10.18632/oncotarget.15180.


Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.

Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG.

Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.


Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.

Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N.

JCI Insight. 2017 Jan 26;2(2):e89904. doi: 10.1172/jci.insight.89904.


Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Mol Cancer Res. 2017 May;15(5):610-618. doi: 10.1158/1541-7786.MCR-16-0291. Epub 2017 Jan 27.


Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.

Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z.

Lancet Haematol. 2017 Feb;4(2):e67-e74. doi: 10.1016/S2352-3026(16)30194-6. Epub 2017 Jan 12.


Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA.

J Immunol. 2017 Feb 15;198(4):1740-1747. doi: 10.4049/jimmunol.1601190. Epub 2017 Jan 11.

Supplemental Content

Loading ...
Support Center